BiKEs and TriKEs have already been developed and evaluated for a broad variety of antigens from different tumors, such as CD30 for Hodgkin’s lymphoma [355,356], HER2 for breast cancer [357,358,359], CD19 for non-Hodgkin’s lymphoma cells [360,361,362], CD33 or CD33 together with CD123 for acute myeloid leukemia [363,364] (NCT03214666), EpCAM for carcinomas [365], CD133 for colorectal cancer [366], EGFR for carcinomas [295,367,368], and B7-H3 for a variety of solid tumors [369]—but not yet for GBM. Here, CD276 is linked to carcinoma.